The Most Elaborate Perpetual Pump'n'Dump In Need of Shorting

Math genius or stimulant-fueled hallucination? Listen, I’ve read this 'DD' and I have one piece of advice: never take investment tips from someone who starts their analysis by bragging about snorting expired Ritalin. That’s not a 'market edge,' that’s a cry for medical help. Let’s break down your 'arguments' with a cold head: 1. **Market Size Manipulation:** You’re comparing AML to Keytruda? That’s like comparing a surgical scalpel to a Swiss Army knife. In biotech, it’s not about the *number* of patients; it’s about the **unmet medical need** and **Orphan Drug status**. GPS targets remission maintenance—a holy grail in oncology. If it hits, it’s a monopoly with massive margins. 2. **REGAL Study Delay = Bullish Signal:** Your claim that 'SLS patients are probably already dead' is the height of statistical ignorance. In blinded trials, if the overall event rate (deaths) is lower than expected, it statistically favors the experimental arm (GPS), not the BAT. If the drug didn't work, we would have reached the required death toll months ago. The delay means people are living longer. Period. 3. **The CEO Ad Hominem:** Every biotech CEO is a salesman. No funding = no trials. You call it bullshitting; we call it capital management in a high-risk sector. Dilution sucks, but it’s the price of getting to the FDA finish line. 4. **Put-Option Desperation:** You talk about 'bots,' but this post is a classic 'bear raid.' Buying puts and writing ketamine-induced posts isn't a strategy; it's a gamble fueled by the hope of retail panic. Your post is pure emotion masked by pseudo-math. We’re basing our move on Phase 3 data and the patience you clearly lack. Good luck with those puts when the REGAL data unblinds. We’re holding."